<aside>

Neurofibromatosis type 2 (NF2), also known as “Wishart disease” is a rare autosomal dominant neurocutaneous disorder characterized by the development of multiple central and peripheral nervous system tumors, most notably bilateral vestibular schwannomas, which are pathognomonic.

</aside>

Legius E, Ludwine Messiaen, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021;23(8):1506-1513. doi:https://doi.org/10.1038/s41436-021-01170-5‌

Legius E, Ludwine Messiaen, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021;23(8):1506-1513. doi:https://doi.org/10.1038/s41436-021-01170-5‌

Etiopathogenesis


Genetic basis:

Feature Description
Gene involved NF2 gene on chromosome 22q12
Protein Merlin (also called schwannomin) – a tumor suppressor
Inheritance Autosomal dominant (but ~50% are de novo mutations)
Tumor predisposition Loss of merlin function leads to uncontrolled proliferation of Schwann cells and meningeal cells

Clinical Features


System Involved Key Manifestations
Auditory/Vestibular Bilateral sensorineural hearing loss, tinnitus, imbalance
Cranial nerves Facial palsy (CN VII), trigeminal neuropathy (CN V)
Spinal cord Schwannomas or intradural extramedullary tumors, ependymomas
Eyes Juvenile cataracts, retinal hamartomas
Skin Few cutaneous neurofibromas, skin plaques (less common than NF1)

Diagnostic criteria


NIH & Manchester Criteria:

Major criteria Minor tumors
1. Bilateral vestibular schwannomas (on MRI)
  1. First-degree relative with NF2 and either: ◦ Unilateral vestibular schwannoma, or ◦ Any two of: meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity | • Multiple meningiomas • Non-vestibular cranial nerve schwannomas • Spinal schwannomas • Ependymomas |

Radiology


https://youtu.be/C0_AqYlNRUE?si=I_dtS-Wv3x8fc1as

MRI Brain: